Key result
Antiarrhythmic drug initiation appears safe across inpatient and outpatient settings despite ~15% early adverse events.
Why the study?
Because prevention is often inadequate and antiarrhythmic drug initiation carries adverse events in the first 24 h, guidance is needed for clinicians starting and maintaining therapy.
This review provides a practical guide for clinicians on how and where to safely initiate antiarrhythmic drugs for atrial fibrillation.
May support outpatient AAD initiation with monitoring; leaves open randomized confirmation of safety.
Atrial fibrillation (AF) is common and occurs in approximately 8% of adults over 65 years of age in the United States. Prevention of AF, with maintenance of healthy weight, treatment of sleep apnea, and regular exercise are key strategies. As prevention is often inadequate, the role of antiarrhythmic drugs (AADs) is paramount. Adverse events are often uncovered in the first 24 h of initiation, and occur approximately 10%-15% of the time, but AADs can still be used safely [2]. Herein, we describe the various categories in a practical guide to initiation to make clinicians more comfortable with starting and maintaining antiarrhythmic therapy in both the inpatient and outpatient setting. The central illustration summarizes the article.
No takes yet. Share an insight, caveat, or question.
Newman et al. (2025) conducted a review in Atrial Fibrillation. Antiarrhythmic drugs was evaluated. Antiarrhythmic drugs can be safely initiated in inpatient and outpatient settings despite adverse events occurring in 10%-15% of cases during the first 24 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: